Extracting the benefits of berberine for colorectal cancer

Lancet Gastroenterol Hepatol. 2020 Mar;5(3):231-233. doi: 10.1016/S2468-1253(19)30430-3. Epub 2020 Jan 8.

Authors

Sohee Kwon¹, Andrew T Chan²

Affiliations

¹ Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
² Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Immunology and Infectious Disease, Harvard T H Chan School of Public Health, Boston, MA, USA. Electronic address: achan@mgh.harvard.edu.

PMID: 31926919
DOI: 10.1016/S2468-1253(19)30430-3

No abstract available

MeSH terms

Adenoma / diagnostic imaging
Adenoma / drug therapy
Adenoma / prevention & control
Antineoplastic Agents, Phytogenic / adverse effects
Antineoplastic Agents, Phytogenic / pharmacology*
Antineoplastic Agents, Phytogenic / therapeutic use
Aspirin / therapeutic use
Berberine / adverse effects
Berberine / pharmacology*
Berberine / therapeutic use
Cardiovascular Diseases / prevention & control
Case-Control Studies
Cell Proliferation / drug effects
China / epidemiology
Colonic Neoplasms / drug therapy
Colonic Neoplasms / metabolism
Colonic Neoplasms / pathology
Colonoscopy / methods
Colonoscopy / standards
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / metabolism
Colorectal Neoplasms / mortality
Colorectal Neoplasms / prevention & control*
Humans
Placebos / administration & dosage
Plants, Medicinal / adverse effects
Plants, Medicinal / chemistry
Platelet Aggregation Inhibitors / therapeutic use
Randomized Controlled Trials as Topic
Recurrence

Substances

Antineoplastic Agents, Phytogenic
Placebos
Platelet Aggregation Inhibitors
Berberine
Aspirin